Paediatric Diseases Working Party (PDWP)
Study type:
Study number:
8417025
Type of treatment:
Diseases:
Short title:
Primary objective:
The primary endpoints are: Platelet count on day +30 and +90 after treatment initiation and +30 after treatment discontinuation
Secondary endpoints are: Reduction of platelet transfusions, Possible adverse events, Relapse of primary condition, Status 1 year post HSCT.
Secondary endpoints are: Reduction of platelet transfusions, Possible adverse events, Relapse of primary condition, Status 1 year post HSCT.
Key inclusion criteria:
- Any patient who received Romiplostim or Eltrombopag post HSCT for thrombocytopenia
- Age at HSCT < 18 years
- Diagnosis after 2013
- Allogeneic and/or autologous stem cell transplantation
- Age at HSCT < 18 years
- Diagnosis after 2013
- Allogeneic and/or autologous stem cell transplantation
Country:
Principal investigator:
Asaf David Yanir
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:
arnaud.dalissier@upmc.fr